CN109152780B - 用于治疗结晶性关节病症的cxcr-2抑制剂 - Google Patents

用于治疗结晶性关节病症的cxcr-2抑制剂 Download PDF

Info

Publication number
CN109152780B
CN109152780B CN201780029205.4A CN201780029205A CN109152780B CN 109152780 B CN109152780 B CN 109152780B CN 201780029205 A CN201780029205 A CN 201780029205A CN 109152780 B CN109152780 B CN 109152780B
Authority
CN
China
Prior art keywords
compound
cxcr
pharmaceutically acceptable
inhibitor
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780029205.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109152780A (zh
Inventor
帕耶尔·纳纳瓦蒂
杰弗里·迈纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Priority to CN202111152242.9A priority Critical patent/CN113893252A/zh
Publication of CN109152780A publication Critical patent/CN109152780A/zh
Application granted granted Critical
Publication of CN109152780B publication Critical patent/CN109152780B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780029205.4A 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂 Active CN109152780B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111152242.9A CN113893252A (zh) 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307348P 2016-03-11 2016-03-11
US62/307,348 2016-03-11
PCT/US2017/021570 WO2017156270A1 (en) 2016-03-11 2017-03-09 Cxcr-2 inhibitors for treating crystal arthropathy disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111152242.9A Division CN113893252A (zh) 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂

Publications (2)

Publication Number Publication Date
CN109152780A CN109152780A (zh) 2019-01-04
CN109152780B true CN109152780B (zh) 2021-10-01

Family

ID=59789863

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780029205.4A Active CN109152780B (zh) 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂
CN202111152242.9A Pending CN113893252A (zh) 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111152242.9A Pending CN113893252A (zh) 2016-03-11 2017-03-09 用于治疗结晶性关节病症的cxcr-2抑制剂

Country Status (10)

Country Link
US (1) US10772886B2 (https=)
EP (1) EP3426253A4 (https=)
JP (2) JP6883917B2 (https=)
CN (2) CN109152780B (https=)
AU (1) AU2017231832B2 (https=)
BR (1) BR112018068393A2 (https=)
CA (1) CA3017345A1 (https=)
CO (1) CO2018010880A2 (https=)
MX (1) MX386771B (https=)
WO (1) WO2017156270A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
BR112020004697A2 (pt) * 2017-09-12 2020-10-27 Ardea Biosciences, Inc. inibidores de cxcr-2 para tratamento de distúrbios
EP3738956B1 (en) * 2018-01-11 2023-03-01 Shenzhen Optimum Biological Technology Co., Ltd Cxcr2 antagonist
CN114286819B (zh) 2019-07-11 2024-03-05 深圳嘉科生物科技有限公司 一种cxcr2拮抗剂的晶型及其应用
KR102260478B1 (ko) * 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097377A (zh) * 2010-07-13 2013-05-08 阿斯利康(瑞典)有限公司 N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形
CN103781781A (zh) * 2011-07-12 2014-05-07 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂的n-(6-((2r,3s)-3,4-二羟基丁-2-基氧基)-2-(4-氟苄基硫基)嘧啶-4-基)-3-甲基氮杂环丁烷-1-磺酰胺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
AU2005210504B2 (en) 2004-01-30 2009-01-08 Merck Sharp & Dohme Corp. Crystalline polymorphs of a CXC-chemokine receptor ligand
KR101280095B1 (ko) 2004-08-28 2013-09-09 아스트라제네카 아베 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2203432A4 (en) 2007-09-21 2011-04-27 Glaxosmithkline Llc PROCESSING METHOD
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
CN102088993A (zh) 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CA2730477A1 (en) 2008-07-16 2010-01-21 Astrazeneca Ab Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
JP2012505160A (ja) 2008-10-06 2012-03-01 カロラス セラピューティクス， インク． 炎症を処置する方法
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
AU2010298249A1 (en) 2009-09-23 2012-04-19 Carolus Therapeutics, Inc. Methods of treating inflammation
WO2011116245A2 (en) 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
CA2811990C (en) * 2010-08-23 2023-03-21 Dean Y. Maeda Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US20180221312A1 (en) 2016-03-11 2018-08-09 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating disorders
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
BR112020004697A2 (pt) 2017-09-12 2020-10-27 Ardea Biosciences, Inc. inibidores de cxcr-2 para tratamento de distúrbios

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097377A (zh) * 2010-07-13 2013-05-08 阿斯利康(瑞典)有限公司 N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形
CN103781781A (zh) * 2011-07-12 2014-05-07 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂的n-(6-((2r,3s)-3,4-二羟基丁-2-基氧基)-2-(4-氟苄基硫基)嘧啶-4-基)-3-甲基氮杂环丁烷-1-磺酰胺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis;Robert Terkeltaub等;《ARTHRITIS & RHEUMATISM》;19980501;第41卷(第5期);900-909 *

Also Published As

Publication number Publication date
JP6883917B2 (ja) 2021-06-09
EP3426253A1 (en) 2019-01-16
JP2019507791A (ja) 2019-03-22
US20180235964A1 (en) 2018-08-23
WO2017156270A1 (en) 2017-09-14
EP3426253A4 (en) 2019-11-06
AU2017231832A1 (en) 2018-10-04
BR112018068393A2 (pt) 2019-01-15
CA3017345A1 (en) 2017-09-14
CN109152780A (zh) 2019-01-04
AU2017231832B2 (en) 2021-11-11
CO2018010880A2 (es) 2018-10-22
US10772886B2 (en) 2020-09-15
CN113893252A (zh) 2022-01-07
JP2021121600A (ja) 2021-08-26
MX386771B (es) 2025-03-19
JP7126014B2 (ja) 2022-08-25
MX2018010946A (es) 2019-05-23

Similar Documents

Publication Publication Date Title
CN109152780B (zh) 用于治疗结晶性关节病症的cxcr-2抑制剂
TW201919599A (zh) 用於治療病症之cxcr-2抑制劑
EP1465638B1 (en) Phosphate transport inhibitors
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN101990434B (zh) 用于治疗沙粒病毒感染的抗病毒药物
US20200281878A1 (en) Cxcr-2 inhibitors for treating disorders
BR112021006002A2 (pt) composições para a redução de ácido úrico sérico
CN111297866B (zh) 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
EP2991733A1 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
HK40058722A (en) Cxcr-2 inhibitors for treating crystal arthropathy disorders
JP7069119B2 (ja) 医薬組成物
US20140127295A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
RU2685408C1 (ru) Гидробромидная соль n-(4-хлор-2-гидрокси-3-((3s)-3-пиперидинилсульфонил)фенил)-n'-(3-фтор-2-метилфенил)мочевины
KR20010021796A (ko) 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
CN113425723B (zh) Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用
US8791110B2 (en) Anti-arenaviral compounds
JP2026511009A (ja) 医薬組合せ及びその使用
CN101904843B (zh) 化合物制备骨破坏抑制剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant